Cupid chairman Halwasiya raises stake to 33.53% as Q1 profit jumps 194%

Cupid chairman Aditya Kumar Halwasiya bought 11 lakh shares, lifting his holding to 33.53%. The consumer healthcare and FMCG company reported Q1 FY27 net profit of Rs 44.15 crore and raised FY27 revenue guidance to Rs 725-750 crore.

— Source publishedMon, 24 Aug, 2026, 16:51 IST·First seen Mon, 24 Aug, 2026, 16:57 IST·Source Business Today · Latest

What happened

Cupid Ltd · Cupid chairman Aditya Kumar Halwasiya raised his personal holding to 33.53% after buying 11 lakh shares. The consumer healthcare and FMCG company

Key facts

  • Aditya Kumar Halwasiya acquired 11,00,000 shares (0.08% equity)
  • Halwasiya's stake rose to 33.53%
  • Promoter and promoter group stake: 46.48%
  • Total shares acquired across three recent transactions: 32,98,538
  • Q1 FY27 net profit: Rs 44.15 crore, up 194% YoY
  • Q1 FY27 total income: Rs 156.98 crore, up 142% YoY
  • Q1 FY27 EBITDA: Rs 60.06 crore, up 265% YoY
  • EBITDA margin: 39%, versus 28% in Q1 FY26
  • FY27 revenue guidance: Rs 725-750 crore
  • FY27 net profit guidance: Rs 210-225 crore

Why this matters

Cupid’s accelerating profitability, upgraded revenue outlook and promoter stake increase strengthen its strategic position as a potential partner or acquisition target in consumer healthcare and FMCG.

What to watch

  • Q2 revenue growth and whether the company maintains the annualized run rate needed for Rs 725-750 crore FY27 revenue.
  • EBITDA margin retention above the mid-30% range after sales-and-marketing and channel-expansion spending.
  • Breakdown of profit growth between operating performance, product mix, acquisition contribution, and any non-recurring items.
  • Receivables, inventory days, operating cash flow, and distributor/channel inventory as growth accelerates.
  • Further promoter shareholding disclosures, pledges, insider transactions, or changes in public float.
  • Management commentary on capacity, product approvals, export demand, competitive intensity, and revised guidance.
  • Increase consumer-healthcare and FMCG distribution reach, particularly in higher-margin branded products and pharmacy/general-trade channels.
  • Use improved profitability to fund advertising, product launches, and possible capacity or working-capital expansion.
  • Provide more detailed investor communication on the sources of Q1 margin expansion, category mix, and the quarterly path to FY27 guidance.
  • Potentially pursue additional promoter or strategic share purchases if market liquidity permits, reinforcing the control position and confidence signal.